DIAGNOSTICS · BIOPHARMA
Selected developments in diagnostics, life science tools and biopharma—with my perspective on what the evidence supports, why it matters, and which decisions it could change.
Cancer blood tests can look for DNA, vesicle markers or the body's protein response. A simpler lab assay could widen access. The economics depend on how many people need follow-up after a positive result.
Read the perspective
The NHS will test whether cancer blood tests can improve urgent referrals for people with abdominal symptoms. Galleri asked whether screening people without symptoms could shift the stage at diagnosis.
Read the perspective
Alongside DNA methylation, blood RNA offers another clue for early cancer detection. Tu-Stroma picked up 92.3% of ovarian cancer precursor cases in retrospective validation. Prospective studies come next.
Read the perspective
Clotting stopped early efforts to block CD40 ligand. Amgen's new approach reduced disease activity in a Phase 3 trial for Sjogren's, an autoimmune disease that can damage the lungs and kidneys.
Read the perspective
Beam says its base-edited sickle cell therapy met the pivotal endpoint of 12 months without severe crises. The release gives the number with enough follow-up, but leaves the actual response rate undisclosed.
Read the perspective
Pelacarsen lowered Lp(a) 78.4% from baseline at one year. Major cardiovascular events occurred in 12.3% on the drug and 12.1% on placebo. The Phase 3 trial missed its primary endpoint.
Read the perspective
FDA cleared Cepheid's PCR panel for Ebola, Marburg, Lassa and Crimean-Congo hemorrhagic fever viruses. One sample can help labs distinguish infections whose early symptoms can look alike.
Read the perspective
Siemens Healthineers has begun carving out its diagnostics business as Olyrian Diagnostics, targeting mid-2028. For labs and partners, continuity of supply and service matters more than the name change.
Read the perspective
Agilent closed its $240M acquisition of digital pathology software maker Proscia. Can tighter integration simplify lab workflows while preserving labs' choice of scanners and software?
Read the perspective
BioNTech is ending a Phase 2 trial of its personalized mRNA vaccine in ctDNA-positive colorectal cancer. The Nov. 3 update gave no reason for the stop. A separate pancreatic trial continues.
Read the perspective
Singapore's planned 450,000-person genome study selects Illumina and a Lucence-QIAGEN-Ultima consortium. The competitive test is delivering a reliable clinical workflow at scale.
Read the perspective
Abbott reports its new Oncodetect MRD test tracks up to 5,000 tumor-specific variants, vs up to 200 previously. Its value will depend on whether earlier signals lead to better treatment decisions.
Read the perspective